Medical Bioethics in Dermatologic Procedures

Area of Science:

• Dermatology
• Cosmetic Surgery
• Medical Device Safety

Background:

• The US Food and Drug Administration (FDA) convened a hearing in November 2008 concerning dermal filler safety.
• Media attention and scientific interest were sparked by the hearing.
• Concerns arose regarding the acceptable risk profile of dermal fillers for elective cosmetic procedures.

Purpose of the Study:

• To analyze the safety data of dermal fillers presented at the 2008 FDA hearing.
• To evaluate the incidence and severity of adverse events associated with dermal filler use.
• To discuss the implications of rare but severe complications in the context of cosmetic enhancement.

Main Methods:

• Analysis of adverse event data from the FDA's Manufacturer and User Facility Device Experience (MAUDE) database.
• Review of 930 reported cases over a six-year period.
• Estimation of complication rates based on reported data.

Main Results:

• An estimated complication rate of 1 in 10,000 dermal filler procedures.
• Reported complications included severe events like facial palsy and anaphylaxis, as well as scarring.
• The data highlighted the occurrence of rare but significant adverse outcomes.

Conclusions:

• The frequency and severity of dermal filler complications warrant careful consideration.
• The acceptability of these risks for elective cosmetic enhancement remains a critical question.
• Further evaluation is needed to balance the benefits and risks of dermal fillers in cosmetic applications.